Brought to you by 
Dr. Reddy's acquires eight US ANDAs from Teva
22 Jul 2022
Executive Summary
Dr. Reddy's Laboratories Ltd. acquired a portfolio of eight Abbreviated New Drug Applications in the US from Teva Pharmaceutical Industries Ltd. for $350mm in cash. The products include buprenorphine/naloxone sublingual film, ethinyl estradiol/etonogestrel vaginal ring, ezetimibe/simvastatin tablets, metformin/saxagliptin ER tablets, tobramycin inhalation solution, phentermine/topiramate ER capsules, imiquimod topical cream, and ramelteon tablets.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dr. Reddy's acquires eight US ANDAs from Teva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice